On July 17, 2026, China's National Medical Products Administration approved iza-bren (izalontamab brengitecan) for adults with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) that progressed after platinum chemotherapy and a PD-1 or PD-L1 inhibitor. The approval gives Chinese oncologists a new second-line option in a disease where responses after chemo-immunotherapy are often short. It is iza-bren's second Chinese indication, following its recent approval for recurrent or metastatic nasopharyngeal carcinoma.
1. What China approved, and for whom
The indication is narrow. Patients must have squamous-cell esophageal cancer, not esophageal adenocarcinoma. Their disease must be recurrent or metastatic, and it must have progressed after a platinum-containing regimen plus PD-1/PD-L1 therapy. That sequence matters because chemo-immunotherapy is now a common first-line approach in advanced ESCC.
The approval rests on PANKU-Esophagus01, also identified as BL-B01D1-305 and NCT06304974. The randomized, open-label phase 3 trial compared iza-bren with the investigator's choice of chemotherapy. According to the July 17 SystImmune release, the study met both primary endpoints at its prespecified interim analysis: progression-free survival and overall survival. The company said the improvement over chemotherapy was statistically significant and clinically meaningful, with a manageable safety profile.
Those are consequential endpoints. Progression-free survival tells doctors how long treatment delayed tumor growth or death. Overall survival asks the harder question: did patients live longer? The press release did not provide the median values, hazard ratios or grade 3/4 adverse-event table, so those figures should not be guessed. What can be said is that the NMPA reviewed a phase 3 study in which both endpoints favored iza-bren.
2. Why the EGFR x HER3 design is different
Iza-bren is not a standard monoclonal antibody and it is not conventional chemotherapy. It is an antibody-drug conjugate, or ADC. The antibody portion recognizes two receptors, EGFR and HER3, that are commonly expressed across epithelial tumors. After binding and internalization, the conjugate releases a topoisomerase-1 inhibitor inside or near the cancer cell, causing DNA damage and cell death.
The dual-target design is the Chinese innovation at the center of this story. A tumor can express EGFR unevenly, HER3 unevenly, or both. Binding two receptors may widen the group of tumor cells the ADC can reach. It may also reduce dependence on one biomarker. That hypothesis still needs tumor-by-tumor confirmation; "dual target" does not automatically mean every EGFR- or HER3-positive cancer will respond.
SystImmune and Sichuan Biokin developed the platform in China. Bristol Myers Squibb collaborates on iza-bren outside China, while Biokin controls the Chinese program. This split matters for medical travelers: China now has the approved ESCC indication, whereas access elsewhere will depend on separate trials and regulatory filings.
3. 2026 cost planning: what is known and what is not
No iza-bren list price appeared in the approval release. Chinese hospitals must complete formulary review and procurement before they can issue reliable international-patient quotations. The table below is a planning benchmark for the prior and comparator treatments, not an iza-bren price claim.
| Treatment benchmark | China | United States |
|---|---|---|
| Platinum-based chemotherapy, per cycle | $3,000-$8,000 | $15,000-$30,000 |
| PD-1/PD-L1 immunotherapy, per cycle | $2,000-$5,000 | $10,000-$25,000 |
| Iza-bren | Price not yet publicly disclosed | Not approved for ESCC |
All figures are 2026 estimates based on published site data. They exclude flights and accommodation. Final cost depends on the hospital, dosing, admission requirements, supportive care and clinical complexity.
Patients from Indonesia, Vietnam, Malaysia, Kazakhstan, Russia and the Middle East should request an itemized quote covering the ADC, premedication, infusion chair or admission, laboratory monitoring, imaging, management of low blood counts and treatment of other toxicities. A single drug figure without those items is not a treatment budget. Our broader cancer treatment cost guide explains the usual billing categories.
4. Chinese hospitals to contact for an ESCC review
Commercial availability will expand after hospital formulary decisions. Until a center confirms stock and a treatment date in writing, patients should treat the approval as regulatory access, not guaranteed immediate access.
Peking University Cancer Hospital, Beijing
The ClinicalTrials.gov record lists Beijing Cancer Hospital as a study location for PANKU-Esophagus01. The center is one of China's major specialist oncology hospitals and has a strong gastrointestinal oncology program. Its international office can review pathology, prior platinum exposure, immunotherapy history and current imaging before discussing iza-bren.
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
This national specialist cancer center has particular strength in thoracic oncology, including esophageal cancer. It is a sensible option for a second opinion on pathology, operability, radiation history and systemic-treatment sequencing. See our guide to China's leading cancer hospitals.
Sun Yat-sen University Cancer Center, Guangzhou
SYSUCC is a high-volume comprehensive cancer center with established care for patients from Southeast Asia. Its gastrointestinal and thoracic teams manage advanced ESCC and complex multimodal treatment. The hospital's location and regional flight links make Guangzhou practical for Indonesian, Vietnamese and Malaysian families. More detail is available in our Guangzhou hospital guide.
Fudan University Shanghai Cancer Center, Shanghai
Fudan's cancer center offers multidisciplinary gastrointestinal and thoracic oncology review, molecular pathology and access to clinical studies. Shanghai is often the easiest entry point for families that need English-language private-hospital support alongside specialist public-center care.
Before travel, send the pathology report, immunohistochemistry, molecular testing if available, CT/PET imaging, discharge summaries and a dated list of prior drugs. Ask the hospital to confirm whether iza-bren is on formulary, the expected start date and the full self-pay estimate. The cancer treatment in China guide covers the document and visa process. Russian-speaking families can also use our Russian patient page; Arabic-speaking families can use the Arabic patient page.
5. Where integrated Chinese-Western medicine fits
Major Chinese cancer hospitals may offer integrated Chinese-Western medicine alongside oncology care. Acupuncture can be considered for selected symptoms such as nausea, pain, dry mouth or sleep disturbance. Some departments also use traditional Chinese medicine (TCM) rehabilitation and carefully selected Chinese herbal medicine.
This is supportive care, not a substitute for iza-bren or another evidence-based antitumor treatment. ADCs can cause cytopenias, fatigue, gastrointestinal symptoms and other toxicities, and herb-drug interaction data for iza-bren are not established. Any herbal formula should go through the treating oncologist and oncology pharmacist. Patients should avoid bringing unlabelled herbs or supplements into an infusion program.
This combination is a genuine feature of Chinese hospital practice: the oncology team treats the cancer, while TCM clinicians may help with symptom control and recovery when the two teams share the medication list. The value lies in coordination, not in claims that acupuncture or herbs can replace systemic therapy.
6. Questions to ask before booking travel
- Does the pathology confirm ESCC rather than adenocarcinoma?
- Has the cancer progressed after both platinum chemotherapy and PD-1/PD-L1 therapy?
- Is iza-bren on the hospital formulary, and can the pharmacy confirm a treatment date?
- What does the written quote include beyond the drug itself?
- Which blood-count, liver-function and imaging checks are required?
- How will complications be handled if the patient returns home between cycles?
- Will any acupuncture, herbal medicine or supplements be reviewed for interactions?
Iza-bren's second Chinese approval is useful precisely because it is specific: a defined drug, a defined patient group and a phase 3 trial with survival endpoints. International patients should now wait for hospital-level pricing and procurement confirmation, not for more promotional adjectives. The next useful public data will be the full PANKU-Esophagus01 efficacy and safety results, including median survival, hazard ratios and adverse events.
Frequently asked questions
Who can receive iza-bren for esophageal cancer in China?
Adults with recurrent or metastatic ESCC whose disease progressed after platinum chemotherapy and PD-1 or PD-L1 therapy fit the approved indication. A Chinese oncology team must still confirm the diagnosis and fitness for treatment.
Is iza-bren approved outside China?
The July 17 announcement concerns the Chinese NMPA approval. SystImmune and Bristol Myers Squibb are developing iza-bren outside China, but overseas access depends on local trials and future regulatory decisions.
How much does iza-bren cost in China?
A public list price was not included in the approval announcement. Request a written hospital quote after formulary listing. Published 2026 benchmarks for other systemic treatments are $3,000-$8,000 per chemotherapy cycle and $2,000-$5,000 per immunotherapy cycle in China; these are not iza-bren price estimates.
Can TCM replace iza-bren or chemotherapy?
No. Acupuncture or Chinese herbal medicine may support symptom control when coordinated with the oncology team, but neither should replace an approved antitumor therapy. Herbs also require an interaction review.